BIOMAT Database Logo BIOMAT Database Logo

[Clinical experimentation with a new hypoglycemic agent (glipizide)]. 1972

C Forattini

UI MeSH Term Description Entries
D007004 Hypoglycemic Agents Substances which lower blood glucose levels. Antidiabetic,Antidiabetic Agent,Antidiabetic Drug,Antidiabetics,Antihyperglycemic,Antihyperglycemic Agent,Hypoglycemic,Hypoglycemic Agent,Hypoglycemic Drug,Antidiabetic Agents,Antidiabetic Drugs,Antihyperglycemic Agents,Antihyperglycemics,Hypoglycemic Drugs,Hypoglycemic Effect,Hypoglycemic Effects,Hypoglycemics,Agent, Antidiabetic,Agent, Antihyperglycemic,Agent, Hypoglycemic,Agents, Antidiabetic,Agents, Antihyperglycemic,Agents, Hypoglycemic,Drug, Antidiabetic,Drug, Hypoglycemic,Drugs, Antidiabetic,Drugs, Hypoglycemic,Effect, Hypoglycemic,Effects, Hypoglycemic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011719 Pyrazines A heterocyclic aromatic organic compound with the chemical formula C4H4N2. Pyrazine
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003510 Cyclohexanes Six-carbon alicyclic hydrocarbons.
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug

Related Publications

C Forattini
[New oral hypoglycemic agent: K 4024 or glipizide. Clinical trial].
December 1972, La Clinica terapeutica,
C Forattini
A controlled clinical trial of a new oral hypoglycemic agent, glipizide (K 4024).
July 1972, Arzneimittel-Forschung,
C Forattini
[A clinical study of a new sulfonylures hypoglycemic agent: glipizide (glibenese)(author's transl)].
May 1975, Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis,
C Forattini
[Clinical evaluation of the oral hypoglycemic agent glipizide].
September 1986, Changgeng yi xue za zhi,
C Forattini
A clinical study of the metabolic effect of a new oral hypoglycemic agent: glipizide.
April 1974, International journal of clinical pharmacology, therapy and toxicology,
C Forattini
[Clinical experimentation with a new antidepressive agent].
November 1972, Minerva medica,
C Forattini
Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use.
January 1985, Pharmacotherapy,
C Forattini
[Clinical experience with glibenclamide, a new hypoglycemic agent].
October 1971, Harefuah,
C Forattini
[Clinical experimentation with a new compound with hypoglycemic activity (chlorpropamide). Preliminary note].
August 1959, Minerva medica,
C Forattini
[Clinical experimentation with a new hepatotropic agent, EU 2200].
November 1966, Lille medical : journal de la Faculte de medecine et de pharmacie de l'Universite de Lille,
Copied contents to your clipboard!